Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province

(2020) Evaluation of plasma Osteopontin level in relapsing- remitting multiple sclerosis patients compared to healthy subjects in Isfahan Province. International Journal of Neuroscience. pp. 493-498. ISSN 0020-7454

Full text not available from this repository.

Official URL: WOS:000500422600001

Abstract

Background: Multiple sclerosis (MS) is known as a neuroinflammatory disease of the central nervous system (CNS). The neuroinflammation may induce pro-inflammatory cytokines such as Osteopontin (OPN). OPN plays an important role in the inflammation by modulating the T helper1 (Th1) and Th17 responses. Since the exact immune pathogenesis of MS is complex and not well defined and many factors are involved, the need to detect more contributing biomarkers may help in setting new therapeutic strategies. Objective: This study tried to compare plasma OPN levels in relapsing- remitting multiple sclerosis (RRMS) patients during the remission phase with healthy subjects in Isfahan province. Materials and methods: In a case-control study, plasma was collected from the 40 RRMS as well as 38 (age and sex matched) healthy individuals as a control group. PlasmaOPN level was measured and compared between the two groups by Enzyme-linked immunosorbent assays (ELISA). Result: Statistical analysis revealed that plasma OPN level was markedly higher in the case group (RRMS patients during the remission phase) compared with the control group (P- value = 0.039). Our results also showed that there was no statistically significant difference in mean of plasma OPN level among RRMS patients who were treated with interferon (IFN)-ss and those who were not (P- value = 0.332). There was also no correlation between OPN plasma level and EDSS score (r = 0.037, P- value = 0.835), age of onset (r = 0.161, P- value = 0.357) and duration of disease (r = 0.121, P- value = 0.490). Conclusion: Higher OPN plasma level in studied patients suggests that OPN increased in RRMS patients who were in remission phase. It could be hypothesized that plasma OPN level may be increased as part of the pro-inflammatory cytokine milieu taking place in MS patients. OPN may not be specific marker for MS, but targeting it might present promising therapeutic effect to MS patients.

Item Type: Article
Keywords: Multiple Sclerosis Relapsing-remitting multiple sclerosis Osteopontin ELISA experimental autoimmune encephalomyelitis cd4(+) t-cells cerebrospinal-fluid ifn-beta in-vivo cytokines pathogenesis expression induction disease Neurosciences & Neurology
Subjects: WL Nervous System > WL 200-405 Central Nervous System. Disorders. Therapeutics
Divisions: Faculty of Health > Department of Epidemiology and Biostatistics
Faculty of Medicine > Department of Basic Science > Immunology Department
Faculty of Medicine > Departments of Clinical Sciences > Department of Neurosurgery
Isfahan Neurosciences Research Center
Page Range: pp. 493-498
Journal or Publication Title: International Journal of Neuroscience
Journal Index: ISI
Volume: 130
Number: 5
Identification Number: https://doi.org/10.1080/00207454.2019.1694925
ISSN: 0020-7454
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/11124

Actions (login required)

View Item View Item